Wird geladen...

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events

BACKGROUND: Nivolumab, an immune checkpoint inhibitor, has revolutionized the treatment of many cancers. Due to its novel mechanisms of action, nivolumab induces a distinct profile of adverse events. Currently, the incidence and risk of developing serious adverse events (SAEs) or fatal adverse event...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Immunother Cancer
Hauptverfasser: Zhao, Bin, Zhao, Hong, Zhao, Jiaxin
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2018
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6171173/
https://ncbi.nlm.nih.gov/pubmed/30285872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0421-z
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!